ARVN Stock Overview
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Arvinas, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$43.24|
|52 Week High||US$97.33|
|52 Week Low||US$34.90|
|1 Month Change||-2.22%|
|3 Month Change||-0.92%|
|1 Year Change||-48.61%|
|3 Year Change||115.98%|
|5 Year Change||n/a|
|Change since IPO||169.41%|
Recent News & Updates
Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Barclays has initiated its coverage on Arvinas, Inc. (NASDAQ:ARVN), a company focused on therapies to degrade disease-causing proteins, with an Overweight rating citing an attractively valued differentiated and potentially disruptive therapeutic platform. The analysts led by Peter Lawson think that the novel protein degraders ARVN is developing could disrupt the conventional small molecule, antibody, and genetic approaches to medicines. With ARVN trading at ~1.9x cash, Barclays cites an encouraging risk-reward setup ahead of data readouts in the second half. The analysts with a $90 per share target on the stock added that clinical data readouts expected in H2 2022 would validate the prospect of ARVN's therapeutic platform to displace oft-used treatments for breast and prostate cancer. This year, ARVN expects to release data on its Pfizer (PFE) partnered breast cancer candidate ARV-471 and prostate cancer candidate ARV-766.
Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Piper Sandler has started coverage of Arvinas (NASDAQ:ARVN) with a buy rating saying that Sanofi's (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech. The firm has a $76 price target (~65% upside based on Thursday's close). Analyst Edward Tenthoff called amcenestrant "an inferior ER [estrogen receptor] degrader" that also has a drug-drug interaction. In contrast, he said that ARV-471, which potently degrades ER, has shown promise in a phase 1 trial. Arvinas is partnered with Pfizer (PFE) on the candidate. Tenthoff mentioned that phase 1 data presented in December showed that RV-471 achieved three partial responses and 16 women had stable disease for a 40% clinical benefit rate. Phase 2 data is expected in Q4 and the companies will begin phase 3 trials in metastatic breast cancer by the end of the year. Seeking Alpha's Quant Rating views Arvinas (ARVN) as a buy with high marks for profitability and growth.
|ARVN||US Pharmaceuticals||US Market|
Return vs Industry: ARVN underperformed the US Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: ARVN underperformed the US Market which returned -23.7% over the past year.
|ARVN Average Weekly Movement||9.2%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ARVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ARVN's weekly volatility (9%) has been stable over the past year.
About the Company
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.
Arvinas, Inc. Fundamentals Summary
|ARVN fundamental statistics|
Is ARVN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARVN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.38|
|Net Profit Margin||-255.87%|
How did ARVN perform over the long term?See historical performance and comparison